CONTE, BENEDETTA
CONTE, BENEDETTA
Dipartimento di Medicina Traslazionale
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
2020-01-01 Prat, A; Guarneri, V; Paré, L; Griguolo, G; Pascual, T; Dieci, Mv; Chic, N; BRASÓ-MARISTANY, F; Vidal, M; Conte, B; Oliveira, M; Saura, C; Pernas, S; Alarcón, J; LLOMBART-CUSSAC, A; Cortés, J; Manso, L; López, R; Ciruelos, E; Schettini, F; Villagrasa, P; Carey, La; Perou, Cm; Piacentini, F; D'Amico, R; Tagliafico, E; Parker, Js; Conte, P
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate
2021-01-01 Poggio, F; Tagliamento, M; Ceppi, M; Bruzzone, M; Conte, B; Fregatti, P; Punie, K; DE AZAMBUJA, E; DEL MASTRO, L; Lambertini, M
Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial
2022-01-01 Conte, B; Montemurro, F; Levaggi, A; Blondeaux, E; Molinelli, C; Cardinali, B; Poggio, F; Buzzatti, G; Bighin, C; Lambertini, M; DEL MASTRO, L
Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers
2021-01-01 Fregatti, P; Gipponi, M; Giacchino, M; Sparavigna, M; Diaz, R; Fioravanti, E; Cornacchia, C; Conte, B; Lambertini, M; Zoppoli, G; Murelli, F; Toni, Ml; Calabro, Mt; Orsino, L; Friedman, D
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
2021-01-01 MARTÍNEZ-SÁEZ, O; Pascual, T; BRASÓ-MARISTANY, F; Chic, N; GONZÁLEZ-FARRÉ, B; Sanfeliu, E; Rodríguez, A; Martínez, D; Galván, P; Rodríguez, Ab; Schettini, F; Conte, B; Vidal, M; Adamo, B; Martínez, A; Muñoz, M; Moreno, R; Villagrasa, P; Salvador, F; Ciruelos, Em; Faull, I; Odegaard, Ji; Prat, A
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
2021-01-01 Schettini, F; Chic, N; BRASÓ-MARISTANY, F; Paré, L; Pascual, T; Conte, B; MARTÍNEZ-SÁEZ, O; Adamo, B; Vidal, M; Barnadas, E; FERNÁNDEZ-MARTÍNEZ, A; GONZÁLEZ-FARRÉ, B; Sanfeliu, E; Cejalvo, Jm; Perrone, G; Sabarese, G; Zalfa, F; Peg, V; Fasani, R; Villagrasa, P; Gavilá, J; Barrios, Ch; Lluch, A; Martín, M; Locci, M; DE PLACIDO, S; Prat, A
De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence
2022-01-01 Conte, B; Soldato, D; Razeti, Mg; Fregatti, P; DE AZAMBUJA, E; Schettini, F; Prat, A; DEL MASTRO, L; Lambertini, M
De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence
2022-01-01 Conte, B.; Soldato, D.; Razeti, M. G.; Fregatti, P.; de Azambuja, E.; Schettini, F.; Prat, A.; Del Mastro, L.; Lambertini, M.
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
2022-01-01 Prat, A; Guarneri, V; Pascual, T; BRASÓ-MARISTANY, F; Sanfeliu, E; Paré, L; Schettini, F; Martínez, D; Jares, P; Griguolo, G; Dieci, Mv; Cortés, J; LLOMBART-CUSSAC, A; Conte, B; MARÍN-AGUILERA, M; Chic, N; PUIG-BUTILLÉ, Ja; Martínez, A; Galván, P; Tsai, Yh; GONZÁLEZ-FARRÉ, B; Mira, A; Vivancos, A; Villagrasa, P; Parker, Js; Conte, P; Perou, Cm
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study
2020-01-01 Blondeaux, Eva; Lambertini, Matteo; Michelotti, Andrea; Conte, Benedetta; Benasso, Marco; Dellepiane, Chiara; Bighin, Claudia; Pastorino, Simona; Levaggi, Alessia; D’ Alonzo, Alessia; Poggio, Francesca; Buzzatti, Giulia; Molinelli, Chiara; Fregatti, Piero; Bertoglio, Sergio; Boccardo, Francesco; Del Mastro, Lucia
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study
2020-01-01 Blondeaux, E; Lambertini, M; Michelotti, A; Conte, B; Benasso, M; Dellepiane, C; Bighin, C; Pastorino, S; Levaggi, A; Alonzo, A; Poggio, F; Buzzatti, G; Molinelli, C; Fregatti, P; Bertoglio, S; Boccardo, F; DEL MASTRO, L
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial
2020-01-01 Lambertini, M; Poggio, F; Bruzzone, M; Conte, B; Bighin, C; DE AZAMBUJA, E; Giuliano, M; DE LAURENTIIS, M; Cognetti, F; Fabi, A; Bisagni, G; Durando, A; Turletti, A; Urracci, Y; Garrone, O; Puglisi, F; Montemurro, F; Cepp, I M; DEL MASTRO, L
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial
2020-01-01 Lambertini, Matteo; Poggio, Francesca; Bruzzone, Marco; Conte, Benedetta; Bighin, Claudia; de Azambuja, Evandro; Giuliano, Mario; De Laurentiis, Michele; Cognetti, Francesco; Fabi, Alessandra; Bisagni, Giancarlo; Durando, Antonio; Turletti, Anna; Urracci, Ylenia; Garrone, Ornella; Puglisi, Fabio; Montemurro, Filippo; Ceppi, Marcello; Del Mastro, Lucia
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial
2020-01-01 Conte, B; Bruzzone, M; Lambertini, M; Poggio, F; Bighin, C; Blondeaux, E; DE LAURENTIIS, M; Valle, E; Cognetti, F; Nisticò, C; DE PLACIDO, S; Garrone, O; Gamucci, T; Montemurro, F; Puglisi, F; Cardinali, B; Fregatti, P; Miglietta, L; Boccardo, F; Cepp, I M; DEL MASTRO, L
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial
2020-01-01 Conte, B.; Bruzzone, M.; Lambertini, M.; Poggio, F.; Bighin, C.; Blondeaux, E.; De Laurentiis, M.; Valle, E.; Cognetti, F.; Nistico, C.; De Placido, S.; Garrone, O.; Gamucci, T.; Montemurro, F.; Puglisi, F.; Cardinali, B.; Fregatti, P.; Miglietta, L.; Boccardo, F.; Ceppi, M.; Del Mastro, L.
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
2021-01-01 Schettini, F; Giuliano, M; Giudici, F; Conte, B; DE PLACIDO, P; Venturini, S; Rognoni, C; DI LEO, A; Locci, M; Jerusalem, G; DEL MASTRO, L; Puglisi, F; Conte, P; DE LAURENTIIS, M; Pusztai, L; Rimawi, Mf; Schiff, R; Arpino, G; DE PLACIDO, S; Prat, A; Generali, D
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
2020-01-01 MARTÍNEZ-SÁEZ, O; Chic, N; Pascual, T; Adamo, B; Vidal, M; GONZÁLEZ-FARRÉ, B; Sanfeliu, E; Schettini, F; Conte, B; BRASÓ-MARISTANY, F; Rodríguez, A; Martínez, D; Galván, P; Rodríguez, Ab; Martinez, A; Muñoz, M; Prat, A
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients
2017-01-01 Conte, B; DEL MASTRO, L
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients
2017-01-01 Conte, Benedetta; Del Mastro, Lucia
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
2020-01-01 Schettini, F; Pascual, T; Conte, B; Chic, N; BRASÓ-MARISTANY, F; Galván, P; Martínez, O; Adamo, B; Vidal, M; Muñoz, M; FERNÁNDEZ-MARTINEZ, A; Rognoni, C; Griguolo, G; Guarneri, V; Conte, Pf; Locci, M; Brase, Jc; GONZALEZ-FARRE, B; Villagrasa, P; DE PLACIDO, S; Schiff, R; Veeraraghavan, J; Rimawi, Mf; Osborne, Ck; Pernas, S; Perou, Cm; Carey, La; Prat, A
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation | 1-gen-2020 | Prat, A; Guarneri, V; Paré, L; Griguolo, G; Pascual, T; Dieci, Mv; Chic, N; BRASÓ-MARISTANY, F; Vidal, M; Conte, B; Oliveira, M; Saura, C; Pernas, S; Alarcón, J; LLOMBART-CUSSAC, A; Cortés, J; Manso, L; López, R; Ciruelos, E; Schettini, F; Villagrasa, P; Carey, La; Perou, Cm; Piacentini, F; D'Amico, R; Tagliafico, E; Parker, Js; Conte, P | |
| Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate | 1-gen-2021 | Poggio, F; Tagliamento, M; Ceppi, M; Bruzzone, M; Conte, B; Fregatti, P; Punie, K; DE AZAMBUJA, E; DEL MASTRO, L; Lambertini, M | |
| Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial | 1-gen-2022 | Conte, B; Montemurro, F; Levaggi, A; Blondeaux, E; Molinelli, C; Cardinali, B; Poggio, F; Buzzatti, G; Bighin, C; Lambertini, M; DEL MASTRO, L | |
| Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers | 1-gen-2021 | Fregatti, P; Gipponi, M; Giacchino, M; Sparavigna, M; Diaz, R; Fioravanti, E; Cornacchia, C; Conte, B; Lambertini, M; Zoppoli, G; Murelli, F; Toni, Ml; Calabro, Mt; Orsino, L; Friedman, D | |
| Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy | 1-gen-2021 | MARTÍNEZ-SÁEZ, O; Pascual, T; BRASÓ-MARISTANY, F; Chic, N; GONZÁLEZ-FARRÉ, B; Sanfeliu, E; Rodríguez, A; Martínez, D; Galván, P; Rodríguez, Ab; Schettini, F; Conte, B; Vidal, M; Adamo, B; Martínez, A; Muñoz, M; Moreno, R; Villagrasa, P; Salvador, F; Ciruelos, Em; Faull, I; Odegaard, Ji; Prat, A | |
| Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer | 1-gen-2021 | Schettini, F; Chic, N; BRASÓ-MARISTANY, F; Paré, L; Pascual, T; Conte, B; MARTÍNEZ-SÁEZ, O; Adamo, B; Vidal, M; Barnadas, E; FERNÁNDEZ-MARTÍNEZ, A; GONZÁLEZ-FARRÉ, B; Sanfeliu, E; Cejalvo, Jm; Perrone, G; Sabarese, G; Zalfa, F; Peg, V; Fasani, R; Villagrasa, P; Gavilá, J; Barrios, Ch; Lluch, A; Martín, M; Locci, M; DE PLACIDO, S; Prat, A | |
| De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence | 1-gen-2022 | Conte, B; Soldato, D; Razeti, Mg; Fregatti, P; DE AZAMBUJA, E; Schettini, F; Prat, A; DEL MASTRO, L; Lambertini, M | |
| De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence | 1-gen-2022 | Conte, B.; Soldato, D.; Razeti, M. G.; Fregatti, P.; de Azambuja, E.; Schettini, F.; Prat, A.; Del Mastro, L.; Lambertini, M. | |
| Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer | 1-gen-2022 | Prat, A; Guarneri, V; Pascual, T; BRASÓ-MARISTANY, F; Sanfeliu, E; Paré, L; Schettini, F; Martínez, D; Jares, P; Griguolo, G; Dieci, Mv; Cortés, J; LLOMBART-CUSSAC, A; Conte, B; MARÍN-AGUILERA, M; Chic, N; PUIG-BUTILLÉ, Ja; Martínez, A; Galván, P; Tsai, Yh; GONZÁLEZ-FARRÉ, B; Mira, A; Vivancos, A; Villagrasa, P; Parker, Js; Conte, P; Perou, Cm | |
| Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study | 1-gen-2020 | Blondeaux, Eva; Lambertini, Matteo; Michelotti, Andrea; Conte, Benedetta; Benasso, Marco; Dellepiane, Chiara; Bighin, Claudia; Pastorino, Simona; Levaggi, Alessia; D’ Alonzo, Alessia; Poggio, Francesca; Buzzatti, Giulia; Molinelli, Chiara; Fregatti, Piero; Bertoglio, Sergio; Boccardo, Francesco; Del Mastro, Lucia | |
| Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study | 1-gen-2020 | Blondeaux, E; Lambertini, M; Michelotti, A; Conte, B; Benasso, M; Dellepiane, C; Bighin, C; Pastorino, S; Levaggi, A; Alonzo, A; Poggio, F; Buzzatti, G; Molinelli, C; Fregatti, P; Bertoglio, S; Boccardo, F; DEL MASTRO, L | |
| Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial | 1-gen-2020 | Lambertini, M; Poggio, F; Bruzzone, M; Conte, B; Bighin, C; DE AZAMBUJA, E; Giuliano, M; DE LAURENTIIS, M; Cognetti, F; Fabi, A; Bisagni, G; Durando, A; Turletti, A; Urracci, Y; Garrone, O; Puglisi, F; Montemurro, F; Cepp, I M; DEL MASTRO, L | |
| Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial | 1-gen-2020 | Lambertini, Matteo; Poggio, Francesca; Bruzzone, Marco; Conte, Benedetta; Bighin, Claudia; de Azambuja, Evandro; Giuliano, Mario; De Laurentiis, Michele; Cognetti, Francesco; Fabi, Alessandra; Bisagni, Giancarlo; Durando, Antonio; Turletti, Anna; Urracci, Ylenia; Garrone, Ornella; Puglisi, Fabio; Montemurro, Filippo; Ceppi, Marcello; Del Mastro, Lucia | |
| Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial | 1-gen-2020 | Conte, B; Bruzzone, M; Lambertini, M; Poggio, F; Bighin, C; Blondeaux, E; DE LAURENTIIS, M; Valle, E; Cognetti, F; Nisticò, C; DE PLACIDO, S; Garrone, O; Gamucci, T; Montemurro, F; Puglisi, F; Cardinali, B; Fregatti, P; Miglietta, L; Boccardo, F; Cepp, I M; DEL MASTRO, L | |
| Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial | 1-gen-2020 | Conte, B.; Bruzzone, M.; Lambertini, M.; Poggio, F.; Bighin, C.; Blondeaux, E.; De Laurentiis, M.; Valle, E.; Cognetti, F.; Nistico, C.; De Placido, S.; Garrone, O.; Gamucci, T.; Montemurro, F.; Puglisi, F.; Cardinali, B.; Fregatti, P.; Miglietta, L.; Boccardo, F.; Ceppi, M.; Del Mastro, L. | |
| Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis | 1-gen-2021 | Schettini, F; Giuliano, M; Giudici, F; Conte, B; DE PLACIDO, P; Venturini, S; Rognoni, C; DI LEO, A; Locci, M; Jerusalem, G; DEL MASTRO, L; Puglisi, F; Conte, P; DE LAURENTIIS, M; Pusztai, L; Rimawi, Mf; Schiff, R; Arpino, G; DE PLACIDO, S; Prat, A; Generali, D | |
| Frequency and spectrum of PIK3CA somatic mutations in breast cancer | 1-gen-2020 | MARTÍNEZ-SÁEZ, O; Chic, N; Pascual, T; Adamo, B; Vidal, M; GONZÁLEZ-FARRÉ, B; Sanfeliu, E; Schettini, F; Conte, B; BRASÓ-MARISTANY, F; Rodríguez, A; Martínez, D; Galván, P; Rodríguez, Ab; Martinez, A; Muñoz, M; Prat, A | |
| Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients | 1-gen-2017 | Conte, B; DEL MASTRO, L | |
| Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients | 1-gen-2017 | Conte, Benedetta; Del Mastro, Lucia | |
| HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis | 1-gen-2020 | Schettini, F; Pascual, T; Conte, B; Chic, N; BRASÓ-MARISTANY, F; Galván, P; Martínez, O; Adamo, B; Vidal, M; Muñoz, M; FERNÁNDEZ-MARTINEZ, A; Rognoni, C; Griguolo, G; Guarneri, V; Conte, Pf; Locci, M; Brase, Jc; GONZALEZ-FARRE, B; Villagrasa, P; DE PLACIDO, S; Schiff, R; Veeraraghavan, J; Rimawi, Mf; Osborne, Ck; Pernas, S; Perou, Cm; Carey, La; Prat, A |